{"id":"traditional-hbv-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain, redness, or swelling"},{"rate":"1-6","effect":"Fever"},{"rate":"5-15","effect":"Fatigue or malaise"},{"rate":"3-10","effect":"Headache"},{"rate":"2-8","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant hepatitis B surface antigen (HBsAg) produced through recombinant DNA technology or purified from plasma. When administered, it triggers both humoral and cellular immune responses, leading to the production of anti-HBs antibodies and memory B cells. This immune response provides long-term protection against HBV infection by preventing viral attachment and entry into hepatocytes.","oneSentence":"The traditional HBV vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:54.293Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals"},{"name":"Post-exposure prophylaxis in non-immune individuals exposed to HBV"}]},"trialDetails":[{"nctId":"NCT04674462","phase":"PHASE4","title":"Understanding Poor Vaccine Responses to Hepatitis B Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-07-07","conditions":"Vaccine Reaction","enrollment":101},{"nctId":"NCT04001322","phase":"NA","title":"Tunatar da ni. The Immunization Reminder and Information SMS System (IRISS)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-15","conditions":"Low Immunization Uptake","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Traditional HBV Vaccine","genericName":"Traditional HBV Vaccine","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Biologic","firstApprovalDate":"","aiSummary":"The traditional HBV vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection. Used for Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals, Post-exposure prophylaxis in non-immune individuals exposed to HBV.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}